https://www.selleckchem.com/pr....oducts/3-deazaadenos
05). When considering interaction effects between evaluation year and other variables, only the interaction between comparative clinical benefit and evaluation year was significant. Specifically, clinically noninferior drugs evaluated after 2014 had 2.85 times the odds of receiving positive recommendations compared with the clinically noninferior drugs evaluated earlier. Implications Recently evaluated drugs are more likely to receive positive reimbursement recommendations, especially those drugs whose comparative
Aimer
Commentaire
Partagez
